WINDTREE THERAPEUTICS INC /DE/ (WINT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5M 3M 4.5M Q4 '13: 387K Q1 '14: 346K Q2 '14: 1.3M Q3 '14: 1.7M Q4 '14: 2.8M Q1 '15: 3M Q2 '15: 2M Q3 '15: 1.5M Q4 '15: 987K Q1 '16: 871K Q2 '16: 902K Q3 '16: 1.8M Q4 '16: 2M Q1 '17: 2.2M Q2 '17: 3.2M Q3 '17: 2.3M Q4 '17: 1.5M Q1 '18: 1.5M Q2 '18: 1.4M Q3 '18: 1.6M Q4 '18: 1.8M Q1 '19: 1.6M Q2 '19: 731K Q3 '19: 502K Q4 '19: 198K Q4 '13 Q4 '14 Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '15: -39.8M Q1 '16: -42.6M Q2 '16: -42.2M Q3 '16: -41.4M Q4 '16: -38M Q1 '17: -32.2M Q2 '17: -28.4M Q3 '17: -25.4M Q4 '17: -22.5M Q1 '18: -19.3M Q2 '18: -16.2M Q3 '18: -14.8M Q4 '18: -16.2M Q1 '19: -18M Q2 '19: -21.5M Q3 '19: -25.2M Q4 '19: -24.9M Q1 '20: -24.9M Q2 '20: -26.4M Q3 '20: -27.9M Q4 '20: -30.3M Q1 '21: -32.7M Q2 '21: -70.1M Q3 '21: -69.5M Q4 '21: -77.3M Q1 '22: -76.5M Q2 '22: -48.7M Q3 '22: -45.2M Q4 '22: -41.3M Q1 '23: -37.2M Q2 '23: -26.4M Q3 '23: -26.4M Q4 '23: -20.6M Q1 '24: -20.8M Q2 '24: -25.5M Q3 '24: -25.6M Q4 '24: -26.1M Q1 '25: -25.8M Q2 '25: -18.4M Q3 '25: -33.5M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q4 '15: -55.2M Q1 '16: -56.9M Q2 '16: -56.2M Q3 '16: -43M Q4 '16: -39.5M Q1 '17: -34.3M Q2 '17: -30.4M Q3 '17: -27.5M Q4 '17: -18.4M Q1 '18: -14.2M Q2 '18: -10.5M Q3 '18: -9M Q4 '18: -20.5M Q1 '19: -22.6M Q2 '19: -25.9M Q3 '19: -29.1M Q4 '19: -27.5M Q1 '20: -27.5M Q2 '20: -30.6M Q3 '20: -32.5M Q4 '20: -32.6M Q1 '21: -35M Q2 '21: -62.8M Q3 '21: -62M Q4 '21: -67.6M Q1 '22: -66.8M Q2 '22: -46.7M Q3 '22: -42.6M Q4 '22: -39.2M Q1 '23: -35.2M Q2 '23: -24.5M Q3 '23: -24.8M Q4 '23: -20.3M Q1 '24: -6M Q2 '24: -11.4M Q3 '24: -9.7M Q4 '24: -1.8M Q1 '25: -16.1M Q2 '25: -14.7M Q3 '25: -40M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q4 '15: -33.5M Q1 '16: -34M Q2 '16: -33.5M Q3 '16: -34.3M Q4 '16: -33.6M Q1 '17: -31.7M Q2 '17: -28.1M Q3 '17: -23.2M Q4 '17: -21M Q1 '18: -16.3M Q2 '18: -14.5M Q3 '18: -14.4M Q4 '18: -15.8M Q1 '19: -22M Q2 '19: -24.8M Q3 '19: -25.4M Q4 '19: -24.7M Q1 '20: -21.4M Q2 '20: -21.8M Q3 '20: -26.2M Q4 '20: -25.3M Q1 '21: -25.9M Q2 '21: -26.2M Q3 '21: -23.3M Q4 '21: -23.7M Q1 '22: -24.3M Q2 '22: -22.2M Q3 '22: -21M Q4 '22: -19.5M Q1 '23: -15.3M Q2 '23: -13.5M Q3 '23: -13.2M Q4 '23: -13.4M Q1 '24: -13.9M Q2 '24: -12.7M Q3 '24: -15.3M Q4 '24: -15.4M Q1 '25: -14.9M Q2 '25: -15.2M Q3 '25: -15.1M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q2 '11: -21.7M Q3 '11: -22.9M Q4 '11: -22.8M Q1 '12: -23.4M Q2 '12: -26.1M Q3 '12: -30M Q4 '12: -33.5M Q1 '13: -38.2M Q2 '13: -39.6M Q3 '13: -39.7M Q4 '13: -41.1M Q1 '14: -41.5M Q2 '14: -41.6M Q3 '14: -42.2M Q4 '14: -41.9M Q1 '15: -40.3M Q2 '15: -39.6M Q3 '15: -36.5M Q4 '16: -33.9M Q1 '17: -31.9M Q2 '17: -28.3M Q3 '17: -23.3M Q4 '17: -21.1M Q4 '19: -24.9M Q2 '21: -26.5M Q3 '21: -23.6M Q4 '21: -23.9M Q1 '22: -24.6M Q2 '22: -22.5M Q3 '22: -21.2M Q4 '22: -19.5M Q1 '23: -15.3M Q2 '23: -13.5M Q3 '23: -13.3M Q4 '23: -13.5M Q2 '12 Q3 '13 Q4 '14 Q1 '17 Q2 '21 Q3 '22 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q3 '12: 43.4M Q1 '13: 43.7M Q2 '13: 49.9M Q3 '13: 54.8M Q4 '13: 73.1M Q1 '14: 6.1M Q2 '14: 85.9M Q3 '14: 85.2M Q4 '14: 6.1M Q1 '15: 6.1M Q2 '15: 85.8M Q3 '15: 105.7M Q4 '15: 8.1M Q1 '16: 8.2M Q2 '16: 8.2M Q3 '16: 8.4M Q4 '16: 8.5M Q1 '17: 450K Q2 '17: 507K Q3 '17: 729K Q4 '17: 2.5M Q1 '18: 3.2M Q2 '18: 3.8M Q3 '18: 3.8M Q4 '18: 7.2M Q1 '21: 17.7M Q2 '21: 26.4M Q3 '21: 26.7M Q1 '22: 566K Q2 '22: 584K Q3 '22: 623K Q1 '23: 48K Q2 '23: 224K Q3 '23: 286K Q1 '24: 9.3M Q2 '24: 11.5K Q3 '24: 17.7K Q1 '25: 1.1B Q2 '25: 4.9M Q3 '25: 26.7M Q4 '13 Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q2 '22 Q1 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6000.00 -4000.00 -2000.00 0.00 2000.00 4000.00 6000.00 Q1 '14: -2.56 Q2 '14: -2.48 Q3 '14: -2.39 Q4 '14: -4.33 Q1 '15: -4.33 Q2 '15: -4.32 Q3 '15: -4.39 Q4 '15: -3.55 Q1 '16: -3.29 Q2 '16: -4.45 Q3 '16: -5.25 Q4 '16: -4.76 Q1 '17: -30.46 Q2 '17: -43.54 Q3 '17: -53.07 Q4 '17: -51.33 Q1 '18: -25.33 Q2 '18: -11.77 Q3 '18: -2.28 Q4 '18: -6.49 Q1 '19: -5.70 Q2 '19: -5.49 Q3 '19: -5.11 Q4 '19: -2.08 Q1 '20: -1.95 Q2 '20: -1.98 Q3 '20: -1.86 Q4 '20: -2.08 Q1 '21: -2.11 Q2 '21: -2.90 Q3 '21: -2.67 Q4 '21: -2.66 Q1 '22: -16.51 Q2 '22: -44.77 Q3 '22: -50.97 Q4 '22: -62.84 Q1 '23: -134.13 Q2 '23: -133.92 Q3 '23: -142.88 Q4 '23: -4768.48 Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.